scholarly journals Pediatric glioblastoma multiforme: A single-institution experience

2012 ◽  
Vol 33 (3) ◽  
pp. 155 ◽  
Author(s):  
Hamid Nasrolahi ◽  
Amir-Abbas Kani ◽  
Mohammad Mohammadianpanah ◽  
Niloofar Ahmadloo ◽  
Ahmad Mosalaei ◽  
...  
2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii71.2-iii71
Author(s):  
Siddhartha Mitra ◽  
Sharareh Gholamin ◽  
Abdullah Feroze ◽  
Irving Weissman ◽  
Samuel Cheshier

2015 ◽  
Vol 50 (1) ◽  
pp. 38-41 ◽  
Author(s):  
Sara Hanaei ◽  
Zohreh Habibi ◽  
Farideh Nejat ◽  
Fatemeh Sayarifard ◽  
Mohammad Vasei

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e14069-e14069 ◽  
Author(s):  
Andrew Samir Iskandar ◽  
Wesley Kerr ◽  
Andrew Hwang ◽  
Stephanie Farrell ◽  
Michael Del Rosario ◽  
...  

2005 ◽  
Vol 75 (2) ◽  
pp. 210-216 ◽  
Author(s):  
Corrie A.M. Marijnen ◽  
Sylvia M.P. van den Berg ◽  
Sjoerd G. van Duinen ◽  
Joan H.C. Voormolen ◽  
Ed M. Noordijk

Medicina ◽  
2018 ◽  
Vol 54 (5) ◽  
pp. 82 ◽  
Author(s):  
Ömer Kartal ◽  
Erman Ataş

Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient.


2016 ◽  
Vol 27 (suppl_9) ◽  
Author(s):  
A.S. George ◽  
A. Philip ◽  
D. Poorna ◽  
D. Makunny ◽  
A. Pillai ◽  
...  

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Melissa Azoulay ◽  
Fabiano Santos ◽  
Luis Souhami ◽  
Valerie Panet-Raymond ◽  
Kevin Petrecca ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document